- Home
- FSFG vs MOLN Comparison
FSFG vs MOLN Comparison
Compare FSFG & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSFG
- MOLN
- Stock Information
- Founded
- FSFG 2008
- MOLN 2004
- Country
- FSFG United States
- MOLN Switzerland
- Employees
- FSFG N/A
- MOLN N/A
- Industry
- FSFG Savings Institutions
- MOLN
- Sector
- FSFG Finance
- MOLN
- Exchange
- FSFG Nasdaq
- MOLN Nasdaq
- Market Cap
- FSFG N/A
- MOLN 195.4M
- IPO Year
- FSFG 2008
- MOLN 2021
- Fundamental
- Price
- FSFG $25.18
- MOLN $5.33
- Analyst Decision
- FSFG Buy
- MOLN
- Analyst Count
- FSFG 1
- MOLN 0
- Target Price
- FSFG $31.00
- MOLN N/A
- AVG Volume (30 Days)
- FSFG 11.8K
- MOLN 6.1K
- Earning Date
- FSFG 02-04-2025
- MOLN 03-13-2025
- Dividend Yield
- FSFG 2.40%
- MOLN N/A
- EPS Growth
- FSFG 66.39
- MOLN N/A
- EPS
- FSFG 1.98
- MOLN N/A
- Revenue
- FSFG $68,091,000.00
- MOLN $7,105,397.00
- Revenue This Year
- FSFG N/A
- MOLN N/A
- Revenue Next Year
- FSFG $2.77
- MOLN $29.41
- P/E Ratio
- FSFG $12.65
- MOLN N/A
- Revenue Growth
- FSFG N/A
- MOLN N/A
- 52 Week Low
- FSFG $14.55
- MOLN $3.32
- 52 Week High
- FSFG $30.94
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- FSFG 41.87
- MOLN 49.14
- Support Level
- FSFG $24.77
- MOLN $5.25
- Resistance Level
- FSFG $26.12
- MOLN $5.33
- Average True Range (ATR)
- FSFG 0.77
- MOLN 0.20
- MACD
- FSFG 0.08
- MOLN 0.02
- Stochastic Oscillator
- FSFG 33.00
- MOLN 44.23
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.